Peptron Inc (087010) - Total Liabilities

Latest as of September 2025: ₩37.42 Billion KRW ≈ $25.36 Million USD

Based on the latest financial reports, Peptron Inc (087010) has total liabilities worth ₩37.42 Billion KRW (≈ $25.36 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 087010 cash flow metrics to assess how effectively this company generates cash.

Peptron Inc - Total Liabilities Trend (2014–2024)

This chart illustrates how Peptron Inc's total liabilities have evolved over time, based on quarterly financial data. Check Peptron Inc asset resilience ratio to evaluate the company's liquid asset resilience ratio.

Peptron Inc Competitors by Total Liabilities

The table below lists competitors of Peptron Inc ranked by their total liabilities.

Company Country Total Liabilities
Corporativo Fragua S.A.B. de C.V
MX:FRAGUAB
Mexico MX$15.09 Billion
Diebold Nixdorf, Incorporated
NYSE:DBD
USA $2.75 Billion
Gaon Cable
KO:000500
Korea ₩791.47 Billion
Shanghai Huafon Aluminium Corp
SHG:601702
China CN¥3.11 Billion
Chicony Electronics Co Ltd
TW:2385
Taiwan NT$51.36 Billion
Hainan Drinda Automotive Trim Co Ltd
SHE:002865
China CN¥12.74 Billion
Fortior Technology (Shenzhen) Co. Ltd. A
SHG:688279
China CN¥149.60 Million
LuxNet
TWO:4979
Taiwan NT$1.64 Billion

Liability Composition Analysis (2014–2024)

This chart breaks down Peptron Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Peptron Inc market cap and net worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric Value Description
Current Ratio 15.86 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity 0.26 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 0.20 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Peptron Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Peptron Inc (2014–2024)

The table below shows the annual total liabilities of Peptron Inc from 2014 to 2024.

Year Total Liabilities Change
2024-12-31 ₩17.18 Billion
≈ $11.65 Million
+4.98%
2023-12-31 ₩16.37 Billion
≈ $11.09 Million
+7.94%
2022-12-31 ₩15.17 Billion
≈ $10.28 Million
-2.70%
2021-12-31 ₩15.59 Billion
≈ $10.56 Million
-61.58%
2020-12-31 ₩40.57 Billion
≈ $27.49 Million
+23.31%
2019-12-31 ₩32.90 Billion
≈ $22.30 Million
+23.40%
2018-12-31 ₩26.66 Billion
≈ $18.07 Million
+549.70%
2017-12-31 ₩4.10 Billion
≈ $2.78 Million
-12.56%
2016-12-31 ₩4.69 Billion
≈ $3.18 Million
+5.96%
2015-12-31 ₩4.43 Billion
≈ $3.00 Million
+0.77%
2014-12-31 ₩4.39 Billion
≈ $2.98 Million
--

About Peptron Inc

KQ:087010 Korea Biotechnology & Medical Research
Market Cap
$2.71 Billion
₩3.99 Trillion KRW
Market Cap Rank
#5248 Global
#129 in Korea
Share Price
₩260500.00
Change (1 day)
-3.52%
52-Week Range
₩157300.00 - ₩386000.00
All Time High
₩386000.00
About

Peptron, Inc. engages in the development of peptide-based medicines. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, premenopausal breast cancer, … Read more